Products Durvalumab / Tremelimumab Combination Therapy
Durvalumab / Tremelimumab Combination Therapy Phase 1/2 Active ⚡ Active Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Mar 7, 2019 → Dec 30, 2024
About Durvalumab / Tremelimumab Combination Therapy Durvalumab / Tremelimumab Combination Therapy is a phase 1/2 stage product being developed by AstraZeneca for Pediatric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03837899. Target conditions include Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03837899 Phase 1/2 Active Mar 7, 2019 Dec 30, 2024 Pediatric Cancer
Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3
Other Products from AstraZeneca